C. Warren Olanow

C. Warren Olanow and his colleagues at Clintrex have advised SynAgile since 2011. As of 2021 Warren serves as SynAgile’s Chief Medical Officer. He is the former Henry P. and Georgette Goldschmidt Professor and Chairman of the Department of Neurology, at the Mount Sinai School of Medicine in New York City, and currently serves as Professor Emeritus in the Department of Neurology and in the Department of Neuroscience at this institution. He is also the Founder and Chief Executive Officer of Clintrex, a clinical research company.

He received his medical degree from the University of Toronto and performed his neurology training at the New York Neurological Institute at Columbia University. He is a Past President of the Movement Disorder Society, Past President of the International Society of Motor Disturbances, Past Treasurer of the American Neurological Association, and past Editor-in-Chief of the journal Movement Disorders. He was a founding member and served on the initial Executive Committee of the Parkinson Study Group.

His research has focused on the cause and treatment of PD and other neurodegenerative diseases. He has led multiple pivotal clinical trials and interacted with regulatory agencies leading to the approval of Pergolide, DBS for tremor, DBS for PD, Safinamide, levodopa/carbididopa intestinal gel, and the apomorphine sublingual strip. He also led important experimental clinical trials including the delayed start study (ADAGIO), the STRIDE-PD study, fetal nigral transplantation, and gene delivery of neurturin.

He has served on dozens of Scientific Advisory Committees for pharmaceutical and biotech companies, including the Michael J Fox Foundation, and the National Space Board Research Institute. He is an honorary professor at University College London (Royal Free Hospital), an honorary member of the French Neurological Society, and an honorary fellow of the Royal College of Physicians in the United Kingdom (FRCP).

He is the recipient of the 2013 movement disorder research award from the American Academy of Neurology and the lifetime achievement award from the International Parkinson and Movement Disorder Society.